FDA Approved: DASATINIB — Supplemental Application (Apotex Corp.)

View source ↗

Summary

FDA approved a supplemental application for dasatinib by Apotex Corp. The approval allows the generic product to be marketed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

SUPPL AP for DASATINIB (DASATINIB)